Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/164.1)
-
Publication number: 20140161792Abstract: The present invention relates to a rhamno-polysaccharide antigen from Enterococcus faecium clonal complex which is useful as a vaccine component for therapy and/or prophylaxis of bacterial infection.Type: ApplicationFiled: May 25, 2012Publication date: June 12, 2014Applicants: FORSCHUNGSZENTRUM BORSTEL, UNIVERSIT TSKLINIKUM FREIBURGInventors: Johannes Hübner, Christian Theilacker, Zbignew Kacynski, Otto Holst
-
Patent number: 8748173Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.Type: GrantFiled: November 17, 2006Date of Patent: June 10, 2014Assignee: UAB Research FoundationInventor: John F. Kearney
-
Publication number: 20140154265Abstract: The present invention relates to replication-competent Arteriviruses having a decreased DUB/deISGylating activity due to a mutation in the PLP2 domain of the non-structural protein nsp2, to their use as a medicament, their use as a vaccine and in prophylaxis, to vaccines comprising such Arteriviruses and to Arteriviral PLP2-ubiquitin complexes.Type: ApplicationFiled: September 24, 2013Publication date: June 5, 2014Inventors: Marjolein Kikkert, Brian Leonard Mark, Puck Bertyne van Kasteren, Terrence William James, Eric John Snijder
-
Publication number: 20140112937Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.Type: ApplicationFiled: March 28, 2012Publication date: April 24, 2014Applicants: FREISTAAT BAYERN REPRESENTED BY JULIUS- -MAXIMILIANS-UNIVERSITAT WURZBURG, MAT-MALTA ADVANCED TECHNOLOGIES LIMITEDInventors: Jan Wesjohann, Günter Sprotte, Ana Maria
-
Publication number: 20140099328Abstract: Antibody product comprising n-specific antibodies characterized in that a) the n-specific antibodies in each case have an antibody content of at least 6/n % by weight of the total antibody component of the antibody product, and b) 2, 3 or more of the n-specific antibodies target lipopolysaccharide-expressing microorganisms, and c) the total amount of n-specific antibodies is 7% by weight of the total anti-body content of the antibody product.Type: ApplicationFiled: March 28, 2012Publication date: April 10, 2014Applicant: MAT-MALTA ADVANCED TECHNOLOGIES LIMITEDInventor: Jan Wesjohann
-
Publication number: 20140093518Abstract: Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.Type: ApplicationFiled: August 26, 2013Publication date: April 3, 2014Applicant: The Scripps Research InstituteInventor: Carlos F. Barbas, III
-
Publication number: 20140065195Abstract: The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.Type: ApplicationFiled: April 30, 2012Publication date: March 6, 2014Applicant: BAYLOR COLLEGE OF MEDICINEInventors: Leonard Weisman, Lingkun Kong
-
Publication number: 20140050741Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.Type: ApplicationFiled: February 17, 2012Publication date: February 20, 2014Applicants: UNIVERSITEIT LEIDEN, UNIVERSITÄTSKLINIKUM FREIBURGInventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
-
Publication number: 20140037649Abstract: Disclosed are methods and apparatus for diagnosis, detection of host response, monitoring, treatment or management of sepsis, infection-negative systemic inflammatory response syndrome (SIRS) and post-surgical inflammation in mammals. More particularly, the present invention discloses marker genes and their splice variant transcripts as well as their expression products, which are useful for distinguishing between sepsis and infection-negative SIRS, including post-surgical inflammation, and to the use of these markers in grading, monitoring, treatment and management of these conditions.Type: ApplicationFiled: November 24, 2011Publication date: February 6, 2014Applicant: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Mervyn Rees Thomas, Glenn Stone
-
Patent number: 8642039Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.Type: GrantFiled: December 21, 2010Date of Patent: February 4, 2014Assignee: KaloBios Pharmaceuticals, INc.Inventor: Geoffrey T. Yarranton
-
Publication number: 20140017257Abstract: A method for large-scale production of anti-NoV antibodies for use as a potential treatment for NoV disease using passive immunization. NoV-specific immunoglobulins (IgY) can be produced by immunizing chickens with NoV P particles. The birds continuously produced high titers of antibodies in their eggs for at least 3 months, in which NoV-specific antibody levels reached 4.7-9.2 mg/egg yolk. The egg yolk antibodies strongly reacted with NoV P particles by both ELISA and Western blot and blocked NoV virus-like particle (VLP) and P particle binding to the histo-blood group antigen (HBGA) receptors with a BT50 of about 1:800. The chicken IgY remain stable at 70° C. for 30 min or treatment at pH 4 to 9 for 3 hr, demonstrating that chicken IgY provides large-scale production of anti-NoV antibodies for use in passive immunization against NoV infection.Type: ApplicationFiled: March 15, 2013Publication date: January 16, 2014Inventors: Xi JIANG, Ying-Chun Dai
-
Publication number: 20140017258Abstract: Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the animals. Methods of making the anti-toxin compositions against the bacterial toxins are also described. The anti-toxin compositions can be effective against pathogenic bacteria and also to decrease the amount of bacterial toxins in the individual, especially in the GI tract. The anti-toxin compositions can also act as anti-inflammatory agents.Type: ApplicationFiled: July 11, 2012Publication date: January 16, 2014Applicant: Camas IncorporatedInventors: Bradley M Mitteness, Connie Phillips
-
Publication number: 20140010824Abstract: Compositions, methods and kits are provided for identifying at least one virulence factor of a Gram-negative bacterial strain, and for preparing attenuated bacterial strain vaccines or a modulator that selectively binds to or inhibits expression of the virulence factor. The Gram-negative bacterial strain is a short facultatively aerobic or micro-aerobic rod or an enteric strain including at least one pathogen selected from the group of: Salmonella, Escherichia, Yersinia, Klebsiella, Shigella, Enterobacter, Serratia, Pseudomonas, and Citrobacter. Novel genes encoding virulence factors are identified, so that non-virulent mutant strains are available for vaccine development.Type: ApplicationFiled: June 7, 2013Publication date: January 9, 2014Inventors: Joan Mecsas, Gregory T. Crimmins, Sina Mohammadi, Erin R. Green, Ralph R. Isberg
-
Patent number: 8623372Abstract: The present invention relates to antibodies immunologically specific for an attaching and effacing Escherichia coli (AEEC) virulence-associated protein, products, compositions and methods and to their use thereof in the prevention of an AEEC infection in a mammal. The antibody of the invention is immunologically specific for an AEEC virulence-associated protein and is capable of preventing an in vivo AEEC intestinal infection when administered to a mammal. The antibody of the invention is preferably useful for preventing the development of A/E intestinal lesions associated with the AEEC. This is achieved by preferably using IgY antibodies immunologically specific for one or more AEEC virulence-associated proteins, such as Eae, Tir, EspA and Paa.Type: GrantFiled: March 26, 2010Date of Patent: January 7, 2014Assignee: Valorisation-Recherche, Societe En commanditeInventors: John M. Fairbrother, Josée Harel, Isabelle Batisson, Francis Girard, Marie-Pierre Guimond
-
Patent number: 8617548Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.Type: GrantFiled: March 30, 2011Date of Patent: December 31, 2013Assignee: Elusys Therapeutics, Inc.Inventor: Leslie S. Casey
-
Patent number: 8617556Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.Type: GrantFiled: November 28, 2011Date of Patent: December 31, 2013Assignees: Genentech, Inc., AIMM Therapeutics B.V.Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
-
Patent number: 8617574Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen from a nontypable Haemophilus influenzae (H. influenzae) species, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a nontypable Haemophilus influenzae species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. More specifically such antigens are produced by or associated with bacterial infections caused by nontypable Haemophilus influenzae.Type: GrantFiled: February 15, 2010Date of Patent: December 31, 2013Assignee: Valneva Austria GmbHInventors: Alexander Von Gabain, Eszter Nagy, Andreas Meinke, Sanja Selak, Markus Hanner, Margarita Smidt, Michaela Weissgram, Birgit Noiges, Stefan Seidel, Julia Bacher, Christina Satke, Wolfgang Schueler, Martin Oleksiewicz
-
Patent number: 8598321Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: GrantFiled: March 21, 2008Date of Patent: December 3, 2013Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Isin N. Geren, Jianlong Lou
-
Patent number: 8591899Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.Type: GrantFiled: March 22, 2010Date of Patent: November 26, 2013Assignee: State of Israel, Represented by Prime Minister's Office, Israel Institute for Biological ResearchInventors: Avigdor Shafferman, Ofer Cohen, Theodor Chitlaru, Sagit Sela-Abramovich, Orit Gat
-
Patent number: 8574853Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: December 2, 2011Date of Patent: November 5, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
-
Patent number: 8563699Abstract: Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein.Type: GrantFiled: January 15, 2010Date of Patent: October 22, 2013Inventors: Samuel Bogoch, Elenore S. Bogoch
-
Publication number: 20130273074Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the treatment and prevention of disorders associated with inflammation of alimentary tract, such as human immunodeficiency virus (HIV) infection and ulcerative colitis and Crohn's disease.Type: ApplicationFiled: October 4, 2011Publication date: October 17, 2013Applicant: IMMURON LIMITEDInventors: Grant Thomas Rawlin, Zeil Rosenberg, Oren Fuerst
-
Patent number: 8541006Abstract: The present invention provides methods and kits for biofilm detection.Type: GrantFiled: July 30, 2008Date of Patent: September 24, 2013Assignees: University of Maryland, Baltimore, The Arizona Board of Regents, a body corporate acting for and on behalf of Northern Arizona UniversityInventors: Jeffrey G. Leid, Timothy L. Vail, Jennifer M. Kofonow, Mark E. Shirtliff, Rebecca A. Brady
-
Publication number: 20130243773Abstract: Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: Merus B.V.Inventors: Patricius Hendrikus Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Patent number: 8518372Abstract: The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor. Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA.Type: GrantFiled: March 23, 2007Date of Patent: August 27, 2013Assignee: University of BaselInventors: Jean Pieters, Rajesh Jayachandran
-
Publication number: 20130216553Abstract: A method for detecting an inflammatory or an autoimmune condition, comprising analyzing bacterial lipids, such as phosphorylated dihydroceramides (PDHC), in a sample; and, comparing results of the analysis of the bacterial lipids in the sample with information on occurrence of the bacterial lipids in a comparable sample, wherein the comparison is indicative of the inflammatory or the autoimmune condition. An example of the autoimmune condition is multiple sclerosis. According to one embodiment, an increased ratio of phosphoglycerol dihydroceramide (PG DHC) to phosphoethanolamine dihydroceramide (PE DHC) in a blood sample indicates a presence of MS in the source patient. The use of PDHCs as biomarkers for detection of MS is described. Antibodies specific to PG DHC or PE DHC are also provided, along with their uses. Also provided are compositions comprising bacteria-originated lipids useful for modulation of immune responses or TLR pathways in humans, animals, and human or animal cells or tissues.Type: ApplicationFiled: October 31, 2011Publication date: August 22, 2013Applicant: University of ConnecticutInventors: Robert B. Clark, Frank C. Nichols
-
Patent number: 8501182Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: GrantFiled: November 19, 2009Date of Patent: August 6, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Publication number: 20130195893Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: ApplicationFiled: March 27, 2013Publication date: August 1, 2013Applicant: The Government of the United States of America as represented by the Secretary of the department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of He
-
Publication number: 20130195892Abstract: The present invention relates to BVD virus and to its uses, to vaccines and combination vaccines comprising such a virus, their use as a medicament, their use in the treatment of Bovine Viral Diarrhoea and to methods for the preparation of such vaccines.Type: ApplicationFiled: September 21, 2011Publication date: August 1, 2013Inventors: Martin Beer, Ilona Reimann, Patricia Koenig
-
Publication number: 20130189280Abstract: The present disclosure relates generally to a structure-modeling approach to identify therapeutic and diagnostic targets on proteins. Means are provided to generate agents which bind and optionally antagonize a particular domain within a protein referred to as a Cleaved_Adhesin Family Domain. In an embodiment, the disclosure is directed to the control of Porphyromonas gingivalis infection or infection by related microorganisms by targeting selected domains on protease-like molecules having a hemagglutinin region. In another embodiment, the present invention enables the modulation or detection of a protein having a Cleaved_Adhesin domain homologous to those in the protease-like molecules.Type: ApplicationFiled: February 11, 2011Publication date: July 25, 2013Applicants: SYDNEY WEST AREA HEALTH SERVICE (SWAHS), THE UNIVERSITY OF SYDNEYInventors: Charles Collyer, Neil Hunter
-
Patent number: 8491894Abstract: The present invention discloses a method for inhibiting the growth of Mycobacterium tuberculosis, comprising: administering at least one selective binding agent such as an anti-CD13 antibody or a CD13 antagonist which can bind a CD13 receptor of a cell to inhibit infection of Mycobacterium tuberculosis. Administration of anti-CD13 antibody can reduce an expression level of the CD13 receptor, inhibit entry of Mycobacterium tuberculosis into monocytes, reduce survival of Mycobacterium tuberculosis in monocytes, and kill Mycobacterium tuberculosis effectively.Type: GrantFiled: June 20, 2011Date of Patent: July 23, 2013Assignee: Mackay Memorial HospitalInventors: Yen-Ta Lu, I-Fang Tsai
-
Patent number: 8491907Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: GrantFiled: July 13, 2010Date of Patent: July 23, 2013Assignee: Amgen, Inc.Inventor: John R. Schreiber
-
Patent number: 8470339Abstract: The present invention discloses new antigens of Mycobacterium avium subsp. paratuberculosis, antigenic compositions comprising at least two of said antigens, as well as epitopes, antibodies or hypervariable fragments thereof and nucleotide sequences coding for them. The present invention also concerns their use in diagnosis and/or vaccination against Mycobacterium avium subsp. paratuberculosis, in mammals, and in particular in cattle, but also in sheep and caprines. The invention also concerns their potential application in diagnosis and/or vaccination against Crohn's disease in human.Type: GrantFiled: November 6, 2007Date of Patent: June 25, 2013Assignees: Universite de Mons, Cerva-Coda, Institut Scientifique de Sante PubliqueInventors: Baptiste Leroy, Ruddy Wattiez, Christiane A. J. Huygen, Virginie Roupie, Marc Govaert, Isabelle Georis
-
Patent number: 8454976Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: July 17, 2008Date of Patent: June 4, 2013Assignees: Syntaxin Limited, Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, John Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8444989Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.Type: GrantFiled: April 14, 2009Date of Patent: May 21, 2013Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Wiliam Charles Ohnesorge, Isabelle Freiin von Richthofen, Marika Genzow, Martina von Freyburg, Carola Kissel, Luc-Etienne Fabry, Knut Elbers, Kathleen Park
-
Patent number: 8435515Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: December 22, 2011Date of Patent: May 7, 2013Assignees: Beth Israel Deaconess Medical Center, Inc., The Brigham and Women's Hospital, Inc.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Patent number: 8431128Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.Type: GrantFiled: December 12, 2011Date of Patent: April 30, 2013Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
-
Publication number: 20130058953Abstract: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.Type: ApplicationFiled: March 2, 2012Publication date: March 7, 2013Applicants: THE UAB RESEARCH FOUNDATION, CEDARS-SINAI MEDICAL CENTERInventors: Kent D. Taylor, Jerome I. Rotter, Charles O. Elson, Stephan R. Targan
-
Publication number: 20130052204Abstract: Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be conjugated to a T-cell dependent antigen. Also provided are methods for synthesizing PGP and methods for conjugating PGP to a T-cell dependent antigen.Type: ApplicationFiled: November 15, 2010Publication date: February 28, 2013Inventors: Clifford M. Snapper, Andrew Lees, James J. Mond, David Schwartz
-
Publication number: 20130045208Abstract: The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.Type: ApplicationFiled: April 3, 2012Publication date: February 21, 2013Applicant: Haptogen, Ltd.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter
-
ANTIGENIC MIMICS OF DISCONTINUOUS EPITOPES OF PATHOGEN RECOGNIZED BY BROADLY NEUTRALIZING ANTIBODIES
Publication number: 20130039927Abstract: The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.Type: ApplicationFiled: February 14, 2011Publication date: February 14, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Stephen Dewhurst, Mark A. Sullivan -
Patent number: 8372412Abstract: The invention provides a bioassay for detection of Mycobacterium tuberculosis infection comprising artificially modified peptide subsequences of the T-cell epitope from M. tuberculosis Ag85B. Particularly preferred peptides have the form: SGGNNSPAX (SEQ ID 26), where X is Methionine (SEQ ID 18), Leucine (SEQ ID 17), Alanine (SEQ ID 15) or Valine (SEQ ID 10) and NNSPAV (SEQ ID 14). The invention also provides peptides for use in such an assay.Type: GrantFiled: December 22, 2006Date of Patent: February 12, 2013Assignee: Rapid Biosensor Systems LimitedInventors: Ram P. Sharma, Amit P. Mehrotra
-
Patent number: 8361441Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Enterobacteriaceae bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal. An antibody and a kit on the basis of the vaccinating method and detecting/diagnosing method are also provided.Type: GrantFiled: September 29, 2009Date of Patent: January 29, 2013Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yung-Luen Shih, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Patent number: 8349326Abstract: The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has one or more monomers that have a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM). Disease agents include bacteria, bacterial proteins, viruses, viral proteins, cancer cells, and proteins or toxins produced therefrom or from other sources such as snakes, insects, plants, etc.Type: GrantFiled: September 24, 2010Date of Patent: January 8, 2013Assignee: Tufts UniversityInventors: Charles B. Shoemaker, Jean Mukherjee
-
Publication number: 20130004510Abstract: Compositions and methods for the treatment or prevention of Gram-negative bacterial strain infection are provided herein. Methods for the manufacture of said compositions are also provided herein.Type: ApplicationFiled: March 11, 2011Publication date: January 3, 2013Inventors: Jan Poolman, Michiel Stork, Johannes Petrus Maria Tommassen, Nathalie Isabelle Devos, Vincent Weynants
-
Patent number: 8343495Abstract: Disclosed are compositions and methods for treating a subject infected with Bacillus anthracis or at risk for infection with B. anthracis. The compositions include and the methods utilize isolated or purified equine antisera against B. anthracis.Type: GrantFiled: January 11, 2010Date of Patent: January 1, 2013Assignee: Auburn UniversityInventor: Kenny V. Brock
-
Patent number: 8324354Abstract: The invention relates to the field of the diagnosis of and vaccination against Streptococcal infections, and to the detection of virulence markers of Streptococci. The invention discloses a method for modulating virulence of a Streptococcus comprising modifying a genomic fragment of the Streptococcus, wherein the genomic fragment comprises at least a functional part of a fragment identifiable by hybridization in Streptococcus suis to a nucleic acid or fragment thereof.Type: GrantFiled: October 31, 2007Date of Patent: December 4, 2012Assignee: Stichting Dienst Landbouwkundig OnderzoekInventor: Hilda Elizabeth Smith
-
Publication number: 20120301480Abstract: Dextrans produced by lactic acid bacteria Leuconostoc mesenteroides and consisting of linear ?1,6-glucan chains modified with short side-chains composed of consecutive ?1,6-linked glucose residues were linked to a carrier protein. Three dextrans, namely Dextran-5K, Dextran-3.5K and Dextran-1.5K, with molecular masses of 5,000 Da, 3,500 Da and 1,500 Da, respectively, were modified with a diamino group-containing linker, followed by the introduction of maleimido functionality and conjugation to thiolated tetanus toxoid (TT), yielding Dextran-5K-TT, Dextran-3.5K-TT and Dextran-1.5K-TT conjugates. Studies performed with post-immune sera of mice and rabbits immunized with dextran-based glycococonjugates demonstrated cross-reactivity with LPS from typeable and non-typeable H. pylori strains and selected mutants. The post-immune sera from rabbits that received the conjugates exhibited functional activity against ?1,6-glucan-positive strains of H.Type: ApplicationFiled: January 10, 2012Publication date: November 29, 2012Inventors: Eleanora Altman, Blair A. Harrison, Vandana Chandan
-
Patent number: 8318438Abstract: We describe examples using aptamers for capturing and reporting the presence of a target, such as a pathogen. Examples described here include a set of aptamers that are specific to F. tularensisis. Other examples described here include an Aptamer-Linked Immobilized Sorbent Assay (ALISA) and dot blot assay. An example of a method provided here comprises: providing a set of DNA sequences that exhibit high binding affinity to target antigen, placing the DNA sequences in a sandwich aptamer-linked immobilized sorbent assay (ALISA), contacting the DNA sequences with a sample, and detecting whether the target is present in the sample. Some alternative implementations may include dot blots and different reporters. Quantum dot sandwich assays and quantum dot de-quenching reporters can be used.Type: GrantFiled: February 27, 2008Date of Patent: November 27, 2012Assignee: The United States of America as represented by the Secretary of the Air ForceInventors: Jeevalatha Vivekananda, Johnathan L. Kiel
-
Patent number: 8309090Abstract: Isolated monoclonal antibodies that bind and/or neutralize anthrax protective antigen (PA) are disclosed as well as hybridomas secreting such antibodies. The invention also provides anti-PA fragments of the antibodies of the invention and recombinantly produced antibodies. Also provided are pharmaceutical compositions containing the antibodies or antibody fragments and uses and methods involving same.Type: GrantFiled: September 3, 2009Date of Patent: November 13, 2012Assignee: Her Majesty the Queen in Right of Canada as Represented by the Minister of National DefenseInventor: Wei-Gang Hu